曲妥珠单抗德鲁替康与化疗治疗HER2阳性转移性乳腺癌患者的成本效益分析：基于DESTINY-Breast02试验

数据集获取（Figshare）

• 源站标题：Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial
• DOI：10.6084/m9.figshare.24754374.v1
• 发布日期：2023-12-06
• 文件数：1 个
• 文件总体积：228.46 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Trastuzumab_deruxtecan_versus_chemotherapy_treated_in_patients_with_HER2-positive_metastatic_breast_cancer_a_cost-effectiveness_analysis_based_on_the_DESTINY-Breast02_trial/24754374

命令行下载

curl -L -o "ierp_a_2291157_sm1643.odt" "https://ndownloader.figshare.com/files/43491858"

文件清单

• ierp_a_2291157_sm1643.odt（228.46 KB）

文件总体积 228.46 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study aims to conduct a cost-effectiveness analysis of trastuzumab deruxtecan versus chemotherapy for HER2-positive metastatic breast cancer from the perspective of the Chinese healthcare system.
A three-state partitioned survival model was constructed to simulate the treatment. The analysis yielded information on the costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses have been carried out to scrutinize the model’s uncertainties
The total cost for the trastuzumab deruxtecan group was found to be $228601.57, while the chemotherapy group incurred a total cost of $84901.38. It was found that the trastuzumab deruxtecan group exhibited an incremental gain of 2.95 QALYs in comparison to the chemotherapy group. However, this additional benefit came at an additional cost of $143700.19 for the trastuzumab deruxtecan treatment, calculated in the ICER at $48711.93/QALY, which surpasses the willingness-to-pay threshold of $37304.34/QALY in China. Sensitivity analyses indicated that the results were robust to variations in key parameters and assumptions.
Trastuzumab deruxtecan was not a cost-effective treatment option for patients with HER2-positive metastatic breast cancer in China. However, the use of trastuzumab deruxtecan may offer a cost-effective treatment alternative provided that its price is diminished.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.24754374.v1（source: https://tandf.figshare.com/articles/dataset/Trastuzumab_deruxtecan_versus_chemotherapy_treated_in_patients_with_HER2-positive_metastatic_breast_cancer_a_cost-effectiveness_analysis_based_on_the_DESTINY-Breast02_trial/24754374）。